Abstract-Aminoglycoside antibiotics have established an important position in medicine and synthetic chemistry in this field has recently been developed. A review is provided of general synthetic schemes which we have developed for the total synthesis of streptomycin, dihydrostreptomycin, kanamycins, butirosin B, neomycin C, and others. Resistent bacteria are a serious subject in present chemotherapy and, the mechanisms of resistance have recently been revealed by medical microbiologists. ln the light of these mechanisms, an effort has been made to synthesise compounds, active against resistent bqcteria, by extension of the above mentioned synthetic schemes and by derivation from natural antibiotics.
INTRODUCTION
The chemistry of aminoglycoside antibiotics originated with the isolation of Streptomycin from the culture of Streptomyces griseus by Woksman and his co-workers in 1944. Streptomycin was remarkably active against gram-negative bacteria and this observationwas especially encouraging since penicillin and sulfonamide drugs were chiefly effective against gram-positive bacteria. Furthermore, streptomycin was remarkably effective in the treatment of tuberculous patients. This Iandmark was followed by the discovery of many allied antibiotics. Micro-organisms of Streptomyces spp. have been the most productive and the aminoglycosides from this source include neomycins (1949), kanamycins (1957), paromomycins (1959), spectinomycin (1961) and others, Furthermore, aminoglycosides have been obtained from cu I tures of Micromonospora, Nocardia, and bacteria; gentamieins (1963) , sisomicin (1970) , and fortimicins (1977) were obtained from Micromonospora, and butirosins (1971) were isolated from a Bacillus. This large group r:i antibiotics is classified as aminoglycosides because they generally contain several amino groups in their glycosidic moieties.
Various aminoglycoside antibiotics have been introduced into and have become established in chemotherapy, being especially useful for the treatment of serious gram-negative infections, although aminoglycoside antibiotics are potentially toxic to varying degrees.
The study of aminoglycoside antibiotics and other sugar-containing antibiotics has provided some of the most fascinating and ehelienging problems in the field of carbohydrate chemistry. Structural, stereochemical, and conformational studies of this group of antibiotics have been expedited particularly by means of 1H-and 1Jc-n.m.r. and mass spectroscopic techniques. During the post ten years, remarkable progress has been seen in the chemistry and biochemistry of aminoglycoside antibiotics.
(1) The challenge affered by the total synthesis of complex aminoglycoside antibiotics has been overcome, although many new structures attractive to synthetic organic chemists still remein to be synthesised.
(2) The biological mechanisms of inactivation of aminoglycoside antibiotics by resistent bacteria have been revealed.
(3) As a result of progress in (1) and (2) the way has been opened to the synthesis of new and improved antibiotics which are remarkably effective against micro-organisms resistent to the natural aminoglycoside antibiotics. This paper is concerned with synthetic aspects. Since several excellent reviews (Refs. [3] [4] [5] [6] of the chemistry of aminoglycoside antibiotics have recently appeared, I will emphasise our recent advances.
TOTAL SYNTHESIS OF AMINOGLYCOSIDE ANTIBIOTICS
ln order to better appreciate the kind of challenges presented by aminoglycoside synthesis, Iet us examine several representative aminoglycoside antibiotics. The streptomycin group of antibiotics e.g. streptomycin (1) and dihydrostreptomycin (2) , is characterised by the presence of L-streptose or its reduced form, L-dihydrostreptose. The aglycone is an aminocyclitol streptidine. These antibiotics contain 2-deoxy-2-methylamino-a-L-glucopyranoside moieties. 
Streptomycin Di hydrostreptomycin
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The neomycins (3, 4) , paromomycins (5, 6) , and lividomycin B (7) are closely related antibiotics. Neomycin was the first antibiotic of this group tobe discovered. The neomycins differ in the configuration of pasition 5 in one of the 2,6-diamino-2,6-dideoxyhexopyranosyl moieties. Paromomycins differ from neomycins by the substitution of an amino group by a hydroxyl group. Lividomycin B corresponds to the 3'-deoxy derivative of paromomycin J • ln these antibiotics, the two 2,6-diamino-2,6-dideoxyhexopyranosyl moieties are linked with the substituents at positions 1 and 2 in cis relationship (1 ,2-cis-pyranosides At that time, the preparation of a-D-glycopyranosides in high yields was an impartant problern in carbohydrate chemistry and the synthesis of aminoglycoside antibiotics involved the formation of such linkages and 1,2-c~.i!-pyranosides, Recent progress in experimental techniques combined with an appreciation of the mechanisms of glycosidic bond formation has made available several useful procedures. Nevertheless, the Koenigs-Knorr condensation is sti II the most widely appl icable to glycoside synthesis. The stereochemical control of the Koenigs-Knorr condensation is unreliable but it has become clear that the participation of the substituent at C-2 plays an important role. Thus, in the gluco series, the use of a nonparticipating C-2 substituentwill favor the formation of a-glycopyranosides, although an appropriate catalyst and solvent must be used.
Our first targets were paromamine and neamine which are pseudodisaccharides. Paromamine (17) (14) ; the total yield of a-glycosides was 85% and, since (14) was a racemate, the desired 4-0-and 6-0-a-glycosyl compounds (15, 16) 
(main product)
The 2-amino-2-deoxy-and 6-amino-6-deoxyglucosyl compounds of 2-deoxystreptamine have antibacterial activity and 3-amino-3-deoxy and 4-amino-4-deoxy-glucosyl compounds (25 and 26) have no antibacterial activity. The a-D-glucosyl compound (27) was prepared by Lemieux and co-workers (Ref. 15) using the glycal-nitrosyl chloride procedure. We further prepared a number of 6-0-glycosyl compounds of deoxystreptamine and found that none of them had antibacterial activity.
5-0-Glycosyl compaunds have also been synthesised • The 5-0 positional isomer of paromamine (28 (13) and (29) .
The foregoing syntheses of pseudodisaccharides provided useful intermediates for further synthesis of more complex aminoglycosides, and we synthesised kanamycins A-C (8-1 O) from the kanosaminyldeoxystreptamine (23), neamine (19) , and paromamine (17), respectively, by way of their suitably protected derivatives and protected glycosyl chlorides (Refs. 18-20).
13 + Of particular interest is the regioselective acylation of NH2-1 of the 2-deoxystreptamine portion ofaminoglycosides, and this was achieved by the above method. 3,4-Di-0-acetyl-2-deoxy-2-N-(p-methoxybenzylideneamino)-6-0-tosyi-D-glucosyl bromide (33) was condensed with a protected 2-deoxystreptamine (34) in dichloromethane containing mercuric cyanide. Since the Ietter aglycone is a racemate, the synthesis yields a mixture of two diastereomeric pseudodisaccharides, which cou ld be separated by column chromatography to give the desired derivative (35) . Removal of the cyclohexylidene group followed by replacement of Ts0-6' with azide, hydrolysis of the acetyl groups, catalytic hydrogenation and benzyloxycarbonylation afforded tetra-N-(benzyloxycarbonyl)neamine (38) in good overall yield. Ketal exchange with 1, 1-dimethoxycyclohexane in the presence of toluene-p-sulfonic acid in N, N-dimethylformamide gave a mixture of mono-and di-cyclohexylidene derivatives. However, we could differentiate the 3',4'-hydroxyl groups from the corresponding entity in the deoxystreptamine portion; the 3',4'-0-cyclohexylidene group on the glycosyl portion is less stable than the 5,6-acetal on the deoxystreptamine portion and the former can be easily removed by addition of methanol to the reaction mixture to give (39) . Further acetylation gave a completely protected derivative (40) . Decyclohexylidenation followed by treatment with sodium hydride in N, N-dimethylformamide afforded the expected cyclic carbamate (42) . Thus, the desired regioselective glycosylation at C-5 of the 2-deoxystreptamine portion became possible. Condensation of (42) with 2,3,5-tri-0-(p-nitrobenzoyl)ribosyl bromide (50) in dichloromethane in the presence of mercuric cyanide gave the protected ribostamycin (43) , which, by hydrolysis with barium hydroxide and benzyloxycarbonylation gave tetra-N-(benzyloxycarbonyl)ribostamycin (44) . Acetalation then gave the tri-0-cyclohexylidene derivative (45) , which has a methoxycyclohexyl form among the three cyclohexylidene groups. The following a-glycosylation reaction is based on our prior findings that the 2-N-(p-methoxybenzylidene) Schiffbase derivatives gave high yields of a-glycosides. Condensation of (51) with 3,4-di-0-acetyl-2-deoxy-2-(p-methoxybenzylideneamino)-6-0-tosyl-a-Dglucopyranosyl bromide (33) in anhydrous chloreform in the presence of silver carbonate, silver perchlorate, and Drierite gave a mixture of glycosides. Hydrolysis of the Schiffbase moiety followed by benzyloxycarbonylation and chromatography on silica gel afforded the desired glycoside (52) in 34% overall yield from (51) . Treatment of (52) with sodium azide then gave (53) and catalytic hydrogenation with polladium black followed by hydrolysis with M barium hydroxide completed the synthesis of neomycin C (4).
(33) , we used 2-amino-2-deoxy-L-glucose instead oF the N-methyl derivotive because we intended to use the Schiffs base For a-glycoside synthesis. Acetalation oF the benzyl dihydrostreptoside by a ketal exchange reaction resulted in the Formation oF an isopropylidene group between the primary and tertiary hydroxyl groups rather than between the secondary and tertiary hydroxyl groups, giving {55). This is a rare structure which proved to be more stable to acids than the usual cyclic acetals. This acetalation enabled us to carry out the Following glycosylation at C-2. Condensation oF {55) with (56) Followed by a sequence oF reactions involving N-methylation and deprotection aFForded the benzyl glycoside (57) oF dihydrostreptobiosamine. On the other hand, the protected streptidine {59), which was soluble in organic solvents, was prepored by a sequence oFreactions {ReF. 34). The protected glycosyl hal ide oF dihydrostreptobiosamine used For glycosylation was {58) which has cyclic carbonate and carbamate groups. Coupling oFC58 and 59)in anhydrous benzene in the presence oF silver carbonate, silver -perchlorate, and a molecular sieve gave a mixture oF glycosides, ( 1) which was separated by chromatography on silica gel to afford the protected dihydrostreptomycin (60), Treatment of (60) with dilute barium hydroxide simultaneously hydrolysed the acetyl, benzoyl, carbamate, and carbonate groups without transformation of the guanidine groups into ureido groups. Subsequent hydrolysis with aqueous acetic acid removed the cyclohexylidene group, and catalytic hydrogenolysis over palladium removed the benzyloxycarbonyl groups, yielding dihydrostreptomycin (2). Streptomycin (1) was synthesised from a protected dihydrostreptomycin by way of the Pfitzner-Moffatt oxidation with methyl sulfoxide, dicyclohexylcarbodi-imide, trifluoroacetic acid and pyridine (Ref. 35 ). Paulsen and his coworkers (Ref. 36) have recently synthesised streptobiosamine via the nitrosoglycal procedure using a new streptose derivative.
SYNTHESIS OF AMINOGLYCOSIDE ANTIBIOTICS ACTIVE AG\INST RESISTANT BACTERIA
Drug resistance is a serious concern in present chemotherapy. Two kinds of resistance mechanism for aminoglycoside antibiotics have recently been revealed invalving change of the 30S ribosemal subunit which is genetically controlled by the bacteria chromosome, and inactivating enzyme production which is genetically carried by plasmid. The former mechanism is found in most of laboratory-developed mutants and rarely in clinical isolates. Most of clinical isolates of drug-resistant bacteria show the Ietter form of resistance. The enzymatic inactivation mechanisms for kanamycin B so far reported are shown below. There are two modes of enzymatic acetylation, specific for NH2-6' and NH2-2', respectively. Resistent bacteria rarely produce adenylyl transferase enzymes to inactivate by adenylylation of H0-2". Moreover, another adenylyl transferase has recently been found to inactivate by adenylylation of H0-4'. However, the most commonly encountered mode of inactivation is 3'-phosphorylation and virtually all aminoglycoside antibiotics (e.g. neomycins, kanamycins and ribostamycin) having a hydroxyl group at position 3' are substrates for these enzymes. There are three different types ( 1-111) of phosphotransferase enzymes which differ in their substrate specificity (Ref. 37) . A research group at our Institute elucidated the structure of kanamycin inactivated by enzymatic phosphorylation in 1967, and their further studies on the substrate specificity of the enzyme showed that the whole kanamycin structure is not required for the enzymatic action, but that only the 4-0-aminoglycosyl-deoxystreptamine portion is necessary; paromamine and neamine arealso phosphorylated at H0-3' by this enzyme. The phosphorylation mechanism of resistance suggested that chemical modification of H0-3' might Iead to a derivative that would be active against resistent bacteria. There are two approaches to new derivatives, namely, total synthesis or modification of the natural an~ibiotics. These syntheses entailed the regioselective removal or modification of amino groups on complex molecules.
Our initial approach involved the total synthesis of 3'-0-methylkanamycin (62) and 3'-deoxykanamycin (61), and we found thot deoxygenation at position 3' has a remarkable effect on the antibacterial activity ( 
3'-Deoxykanamycin A : R = H 3'-0-Methylkanamycin A : R = OMe
Next, we contemplated the transformation of natural aminoglycosides into their 3'-deoxy derivatives. However, since deoxyaminosugars are a comparatively unknown class of compounds, we first studied their preparation. These studies will not be referred to in detail here, but a deoxy derivative was prepared (Ref. The deoxygenation of kanamycin B (9) was accomplished (Ref. 43 ) as shown below. The protected kanamycin (67) was regioselectively mesylated to give ~8),which, on treatment with sodium iodide and zinc dust, gave the 3' ,4'-unsaturated derivotive (69). Catalytic hydrogenation then gave the 3' ,4'-dideoxy derivotive (70). Decyclohexyl idenation followed by removol of the other protecting groups by hydro Iysis with barium hydroxide yielded 3' ,4!dideoxykanamycin B (71, "'30% from kanamycin B).
lts antibacterial spectrum is shown in 
B
An improved synthesis of dibekacin is shown below. ln general, protection of the amino groups is a prerequisite for transformation oftheaminoglycoside molecule, but, in this synthesis, we protected H0-4",6" prior to the protection of amino groups. Thus, kanamycin was first converted into its pentatoluene-psulfonate salt (72) in order to raise the solubility in organic solvents. Controlled transketalization with cyclohexanone dimethyl ketal then gave 4",6"-0-cyclohexylidenekanamycin B (73) which retained strong antibacterial activity. The amino groups of (73) were benzyloxycarbonylated to give (74). Benzyl sulfonylation was then used in an approach to 3',4'-unsaturation. Treatment of (74) with benzylsulfonyl chloride in pyridine at -20° for several hours gave the 3' ,4' ,2"-tri-0-benzylsulfonyl derivative (75, 98%) without benzylsulfonylation of H0-5 of the deoxystreptamine portion. Treatment of (75) with sodium iodide and zinc dust in N, N-dirre thylformamide gave the 3' ,4'-unsaturated derivative (76, 86%). Decyclohexylidenation gave (77), and subsequent treatment with sodium in liquid ammonia readily removed the N-benzyloxycarbonyl and 0-benzylsulfonyl groups to give (78), which was converted into dibekacin by catalytic hydrogenation. The overall yield of dibekacin from kanamycin 8 was )50% (Ref. 44) . The intermediate (67) was also useful for the synthesis of 3'-deoxykanamycin 8 which was one of the desired derivatives and is identical with tobramycin. Tosylation of (67) was selective for H0-3' and iodination with sodi um iodide in N, N-dimethylformamide afforded the iodo derivative (80) probably through an oxazoline intermediate formed by participation of the ethoxycarbonyl group at C-2'. Finally, catalytic hydrogenation with Raney nicke( followed by deprotection gave 3'-deoxykanamycin 8 (32) identical with tobramycin (Ref. 45 ),
The inactivation mechanisms for ribostamycin {81) are shown below. There are four different types of phosphotransferase enzyme1 which differ in their substrate specificities. Phosphotransferase -1 phosphorylates H0-3' as weil as H0-5" on the ribose portion 1 but does not inactivate butirosins1 whereas phosphotransferase-11 phosphorylates butirosins at position 3' and does not inactivate 3'-deoxyribostamycin and lividomycins (3'-deoxy compounds). Another phosphotransferase recently discovered preferentially phosphorylates H0-5" on the ribose portion. Phosphotransferase-111 inactivates both butirosins and lividomycins.
(81) Inactivation of Ribostamycin
Reaction sequences similar to those mentioned above allowed the synthesis of 3'-deoxy- 
Mannasyl Mannasyl
The deoxygenation of aminoglycosides is of current interest, and a research group at the Takeda Chemical lndustries recently reported a new method involving a combination of enzymatic and chemical reactions; 3'-phosphates of aminoglycosides were prepared using the phosphotransferase enzymes and then converted into 3'-chloro derivatives by treatment with trimethylchlorosilane, which, on subsequent catalytic dechlorination, gave 3'-deoxy derivatives (Ref. 51 ).
Another important modification of aminoglycoside antibiotics was suggested from the structures of the butirosins; butirosin B {31) is a derivative of ribostamycin acylated with the {S)-{-)-4-amino-2-hydroxybutyryl {AHBA) side chain attached to NHT 1 of the deoxystreptamine moiety. A comparison of the antibacterial spectra of the butirosins and ribostamycin {81) showed that the former have a broader spectrum than ribostamycin, inhibiting some kanamycin-resistant bacteria including Pseudomonas strains. This relationship suggested that a favorable effect was obtained by acylation of NH2-l of the deoxystreptamine moiety in aminoglycoside antibiotics with this peculiar amino acid. Kanamycin modified in this way {89) was reported by Bristoi-Banyu investigators in 1972 and was found {Ref. 52) to be equally or more active than kanamycin against both kanamycin-sensitive and resistent organisms. This derivative is assigned the generic namearnikaein and was recently commercialised. We have synthesised 1-N-AHBA derivatives of dibekacin {71) {Ref. 53) and lividomycins {7, 86) {Refs. 54, 55), 3'-deoxybutirosins {Refs. 56, 58), 3' ,4'-dideoxybutirosin B {Ref. 59) and others.
The selective acylation of NH2-l of deoxystreptamine moiety is generally difficult. However, this acylation has been achieved in several cases through the above mentioned cyclic carbamate intermediate. 
{89} Arnikaein
The transformation of ribostamycin {81) into 3'-deoxybutirosin B {99) is shown below. The starting material {45) is an intermediate in the synthesis of butirosin 8. Controlled hydrolysis of {45) with acetic acid removed the 5"-0-{methoxycyclohexyl) group to give{90),which, on treatment with sodium hydride in N, N-dimethylformamide, gave the cyclic carbamate{91 ). After acetylation of H0-5", the cyclohexylidene group was removed by controlled hydrolysis to give the 3',4'-diol {93). Selective tosylation of H0-3' followed by iodination and catalytic hydrogenation gave the 3'-deoxy derivative{96). Mild hydro Iysis of the carbamate with dilute barium hydroxide gave{97), which, after 1-N-acylation and deprotection, provided 3'-deoxybutirosin 8 {99) {Ref. 56). This semisynthetic antibiotic shows an excellent antibacterial spectrum, including activities against resistent bacteria which produce phosphotransferase II and inactivate butirosins. The 1-N-acylation of lividomycin A (86), which is a pseudopentasaccharide antibiotic, is shown below. Benzyloxycarbonylation of (86) followed by acetalation with benzaldehyde dimethyl acetel gave the penta-N-benzyloxycarbonyl-tri-0-benzylidene derivative (1 00), which, on treatment with sodium hydride in N ,N-dimethylformamide, gave the cyclic carbamate (1 01 ). Cyclic carbamate formation between NH2-2"' end H0-3"' on the neosamine B moiety (L-ido form) did not occur,suggesting that this moiety may be in 1C-Iike conformation which hinders the carbamate formation. Mild alkaline hydrolysis of the carbamate followed In this derivative, NH2-6' is further methylated in order to prevent 6'-N-acetylation by the acetyltransferase enzyme. Table 2 shows the antibacterial spectra of this and another derivative, 6'-N-methyldibekacin, which wehavealso preparedo This derivative inhibits almost all inactivations by phosphotransferases, adenylyltransferases, and acetyltransferases. A combination of deoxygenation, N-acylation, and Nmethylation provides significant activity against many resistent organisms. However, this compound was not commercial ised because the cost was too high o 6' 4 ,~H~e 
1.56
Po aeruginosa TI-13 6o25 12.5 P-(1) (3'-0) P. aeruginosa GN315 6o25 12.5 6'-N-Ac P. aeruginosa 99 25 12o5 GM-3-N-Ac ln 1968 Umezawa and his co-workers reported that streptomycin (I) was inactivated by adenylylation 1 and in the same year 1 they and Davies and his co-workers proved that the inactivated product was the 3"-0-adenylyl derivative. Subsequently 1 phosphorylation of H0-3" by a phosphotransferase was reported 1 and 1 recently 1 other inactivations by phosphorylation and adenylylation of H0-6 of streptidine moiety have been described. Among these inactivating enzymes1 the 3"-0-phosphotransferase is frequently found in clinical isolates.
We have recently synthesised the 3"-deoxydihydrostreptomycin (113) (Refs. 61 1 62) . The startins substance was benzyl dihydrostreptobiosaminide (57) obtained from dihydrostreptomycin by benzyl alcoholysis. N-Benzyloxycarbonylation of (57) followed by isopropylidenation and mesylation gave (I 05). Treatment of the 3'-0-mesyl derivative with sodium acetote in 2-methoxypropane gave the N1 0-carbonyi-L-allo derivative (I 06). Mild hydro Iysis of the cyclic carbamate followed by N-acetylation gave (I 07)1 which 1 on eh Iorination with sulfuryl chloride afforded the 3'-chloro derivative (I 08). Reduction with tributyltin hydride then gave the desired 3'-deoxy compound (I 09). Then1 by a sequence of reactions1 the isopropylidene group on the dihydrostreptose moiety was converted into a cyclic carbonate group to give (II (11 0 )with thionyl chloride. Compound (111) was then condensed with the protected streptidine (59) , an aglycone prepared previously in the total synthesis of dihydrostreptomycin, and since it is a racemate, the condensation product is a mixture of glycosides. Column chromatography gave(112) and deprotection gave the 3"-deoxydihydrostreptomycin (113), the antibacterial spectrum of which is shown in Table 3 , compared tothat of dihydrostreptomycin. This is the first successful modification in the streptomycin series, and the product shows remarkable activities against strains producing the phosphotransferase or adenylyltransferase as weil as against normal strains. 
O OBn
3"-Deoxydihydrostreptomycin ( 107) ln conclusion, the synthetic studies directed towards the aminoglycoside antibiotics now cover a wide area, and many references could not be included in this paper. For instance, there are extensive studies on gentamicins, a large group of aminoglycosides, by Daniels and associates of the Sehering Corporation. Nevertheless, I hope that my approach indicated the present status of this field.
lt has been shown that specific deoxygenation, N-acylation and N-alkylation are successful in increasing the activities of aminoglycoside antibiotics against resistent organisms. Moreover, combinations of these modifications are even more effective. There is a Iimit to the number of functional groups which can be removed or modified, but we have learned from Nature the structures of aminoglycosides such as spectinomycin, kasugamycin, sisomicin, butirosins, validamycins, apramycin, fortimicins, and others. ln view of probable discoveries of new aminoglycosides, growing knowledge of mechanisms of antibiotic action and resistance, and developments in synthetic chemistry, further advances in useful aminoglycoside antibiotics may be expected.
